Joining the fight against prostate cancer with Prostate Cancer UK

Dataro recently joined forces with the team at Prostate Cancer UK to test how AI predictive modelling would perform against traditional list selection methods in an Autumn Appeal. The results showed that Dataro’s selections increased revenue by over £11,000 and attracted more than 440 new gifts that otherwise would have been missed, laying a solid foundation for future appeals.

Key results

  • Over 440 extra gifts that would have been missed
  • Over £11,000 additional raised
  • Significant increase in response rate

How we did it

Prostate Cancer United Kingdom is innovating in the way it uses data to select which supporters to contact with which campaigns. Traditionally, charities have used simple models or manual methods such as RFM (Recency, Frequency, Monetary value) analysis to create segments that group supporters together based on recent giving history.

Dataro’s software uses machine learning to analyse patterns of donor behaviour across all fundraising campaigns and understand each donor’s unique giving journey. Each donor is then given a ‘propensity score’ reflecting their probability of giving in an upcoming appeal. This process was conducted using Dataro’s integration with Blackbaud Raiser’s Edge CRM.

In this experiment, we compared the results from both approaches using the same methodology as with organisations such as Parkinson’s UK and Greenpeace:

  1. We generated propensity scores for every donor reflecting their propensity to give to the direct mail appeal. Using these scores, we generated a recommended campaign list.
  2. Prostate Cancer UK compared the Dataro list against its own proposed campaign list to identify three categories of donor:
    1. Donors appearing in both lists were labelled blue;
    2. Donors Prostate Cancer UK selected but which Dataro would removed were labelled red; and
    3. Donors Dataro selected but which Prostate Cancer UK had not chosen were labelled green.
  3. The appeal was sent to all donors from both lists, allowing us to compare responses from the Dataro selections vs the Prostate Cancer UK selections.

Analysing the Results

The results were clear. Dataro’s machine learning list performed better than the classic list across all metrics. Critically, the results showed:

  • Organisations not using machine learning are missing out on a significant number of donations in their appeals
  • Organisations typically include far too many donors, resulting in wasted mail and increased cost

Net Revenue

A key test of performance is net revenue. In this case, net revenue takes into account the costs of the campaign and the total amount raised. We could see that the net return from the blue segment was the highest, but that the extra donors selected by Dataro significantly outperformed the extra donors selected using the classic model. This resulted in an overall 3.6% increase in net returns.

Response Rate

Response rates are useful to track the effectiveness of list selections. In this analysis, we can see how the extra donors selected by Dataro responded far better than the extra donors selected with RFM, with a response rate of over 8% compared to less than 3%. The donors appearing in both lists also performed strongly, with a response rate over 10%.

ROI

A final key indicator for the campaign is the ROI, which in this case takes into account the total mail cost and the return from the Dataro list vs the classic segmentation. The results showed an ROI of over 10 from the Dataro campaign compared to 8.7 from the normal selection, an increase of 14.8%.

These results again show that better campaign selections driven by machine learning predictive modelling result in more gifts and increased returns in direct mail appeals, paving the way towards higher performing appeals in the future.

What they said

“One man dies every 45 minutes from prostate cancer; it’s now the most commonly diagnosed cancer in the UK, and the Coronavirus pandemic has made living with a diagnosis only harder. Working with Dataro has been great, and it’s work like this that will help Prostate Cancer UK reach its ultimate goal to saves men’s lives.””

Holly Matthews

Direct Marketing Manager

More Case Studies

How Save The Children used AI to engage more mid-value donors to support children in need

How Save The Children used AI to engage more mid-value donors to support children in need

Save the Children is the world’s leading aid and development agency dedicated to protecting children and helping them reach their full potential. In 2022, Save The Children Netherlands partnered with Dataro to see if they could convert more of their mass-market donors (single giving, recurring giving, multi-donors) to

Read more
$831k in Extra Funding Secured in One Year with AI Donor Predictions

$831k in Extra Funding Secured in One Year with AI Donor Predictions

A leading international nonprofit dedicated to improving the lives of people with disabilities in developing countries partnered with Dataro seeking better direct mail appeal returns. This charity relies on the success of its direct mail appeal program to fund its important work and implements approximately 12 campaigns per

Read more
Engaging the Right Mid-Value Prospects and Donors to Support Displaced People Worldwide

Engaging the Right Mid-Value Prospects and Donors to Support Displaced People Worldwide

Australia for UNHCR is the UN Refugee Agency’s national partner in Australia. It raises funds and awareness to support displaced people worldwide. Since late 2021, the charity has used Dataro’s AI donor predictions to improve fundraising ROI in its appeals program. In 2023, the UNHCR team wanted to

Read more
Transforming the Future of Pancreatic Cancer with AI Donor Predictions

Transforming the Future of Pancreatic Cancer with AI Donor Predictions

Pancreatic Cancer UK is working to transform the future for everyone affected by pancreatic cancer. Through the generous support of their donors, they fund research breakthroughs, campaign for changes to treatment and care, and provide support to those affected by pancreatic cancer. In 2021, Pancreatic Cancer UK partnered

Read more